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A substantial proportion of the UK population are afflicted by cartilage damage every year, as
a consequence of sporting injury or osteoarthritis. Current treatment therapies available are in-
adequate at providing a lasting result, while developing cell-based therapies present significant
costs, resulting from strict regulations surrounding manufacturing processes. An economical
solution was sought through development of an injectable bedside technology in the form of
an alginate fluid gel-microenvironment and scaffold, capable of sustaining and delivering cells
with chondrogenic potential, as well as retaining them during the healing process. Initial work
investigated the effect of polymer concentration, with 2% gels demonstrating greater retention
within model defects and superior self-setting ability. Subsequent analysis of the fluid gel mi-
crostructure revealed alignment of strands or fibres within the gel network that may influence its
mechanical properties. Successful incorporation of MC3T3 fibroblast cells within alginate fluid
gels was achieved, with the majority of cells expressing excellent viability over a 7-day culture
period. Similar results were seen following metabolic activity analysis of BMSCs and human
BMAC cells over 14-day and 21-day culture periods. Release profile studies also demonstrated
steady release of KGN from the fluid gel matrix over 7 days, with no evidence of immediate
burst release.
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CHAPTER 1
INTRODUCTION
Cartilage damage is a common occurrence, particularly amongst younger populations, with
approximately 10,000 people in the UK seeking treatment for this disorder each year [1, 2].
Forgoing treatment could result in chronic pain and the development of osteoarthritis, which
presents a significant economic burden due to the cost of treatment and impact of disability
[3]. Articular cartilage is designed to enable the smooth mobility of joints and protection of
subchondral bone from impact and stress [4]. It is composed of hyaline cartilage in the form of
an extracellular matrix, which contains a sparsely distributed population of chondrocyte cells
amongst other constituents including collagen, proteoglycans and water. The most abundant
type of collagen present is type II (90-95%), which is arranged into fibrils and fibers entangled
with proteoglycans. There are a range of proteoglycans present in articular cartilage, such as ag-
grecan, biglycan and decorin, but aggrecan is present in the largest quantities and is able to form
proteoglycan aggregates with hyaluronan [5]. Unfortunately, articular cartilage is avascular in
nature, which limits its ability for repair or regeneration. Therefore, if damage does occur, scar
tissue is formed from the subchondral bone, which lacks type II collagen and contains different
proteoglycans, resulting in a weaker biomechanical structure [1].
1.1 Current treatment therapies
There are currently a number of treatment therapies available for chondral lesions, including mi-
crofracture, osteochondral allografts and autologous chondrocyte implantation (ACI). However,
none of these have yet been able to offer a long-term durable solution [1, 4]. Whilst microfrac-
ture enables the release of bone marrow stem cells (BMSCs) by perforating the subchondral
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bone, it results in the formation of fibrocartilage, which is mechanically inferior to hyaline car-
tilage and contains a larger amount of type I collagen [6]. Additionally, osteochondral allografts,
despite demonstrating feasible transplantation of chondrocytes from cadavers without creating
an immunological response, present possible risks of disease transmission and supply is un-
likely to meet the overall demand for replacement tissue in a resource efficient manner. [1, 6].
ACI is one of the more recently developed cell-based treatment strategies, where autologous
chondrocytes are first collected and expanded through cell culture, before being reimplanted
beneath a periosteal patch [6]. However, studies have revealed that the cells can undergo a
change in phenotype during expansion, diminishing their ability to form type II collagen [1, 7].
The treatment cost is also extremely expensive (around £25,000) and, due to a lack of clini-
cal evidence of a substantial cost-benefit gain as reviewed by the National Institute for Health
and Care Excellence (NICE), there are a limited number of hospitals offering this procedure [8].
An alternative option for therapy that has demonstrated comparable efficacy to ACI, is the use
of BMSCs with chondrogenic potential, which have improved proliferation rates compared to
chondrocytes and, importantly, permit greater control over differentiation to (and maintenance
of) a chondrogenic phenotype. They have also exhibited great potential in improving quality
of life in older population groups (over 45 years of age), where ACI has been less effective
[9]. However, extensive manipulation of cells, such as cell expansion (culture), results in their
classification as an Advanced Therapy Medicinal Product (ATMP) by the European Medicines
Agency [10]. Such processes require production under Good Manufacturing Practice (GMP)
conditions, which has associated costs in terms of investment and labour that decrease the prob-
ability of acceptance by the National Institute for Clinical Excellence (NICE), and thus the
feasibility of the treatment being implemented by national health service providers [11, 12].
The aim of this project was to provide an economical solution to aid articular cartilage damage
in the form of a bedside technology, which is capable of sustaining cells of chondrogenic poten-
tial and delivering them to the defect site whilst retaining the cell population during the healing
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process. The gel system will therefore need to provide the correct biochemical microenviron-
ment to direct their lineage down a chondrogenic route. Consequently, a recently discovered,
small nonprotein molecule kartogenin (KGN), that has been shown to stimulate selective dif-
ferentiation of stem cells into chondrocytes, could facilitate the differentiation of progenitor
cells when incorporated into the fluid gel microenvironment [13, 14].The objective with this
approach is to make more effective use of cell-based therapies by providing a mechanism of
delivery and retention of both the cell population and the biochemical environment (the cell
’niche’) required to direct cell fate, and thus maximise the chance of achieving successful re-
generation of the affected tissue.
There has continually been significant interest in the application of gels formulated using a
range of synthetic and biological polymers in tissue engineering and specifically, for cartilage
repair and regeneration [15, 16]. This stems from their numerous desirable properties that in-
clude excellent biocompatibility and similitude to the extracellular matrix (ECM) of biological
tissues [16]. Although various biopolymers can be used to create gels, including agarose and
κ-carrageenan, for this work two different grades of sodium alginate were chosen, due to its
resistance to thermo-reversible effects which κ-carrageenan, agar and gellan are impartial to
[17, 18]. Alginate was also chosen due to its ease of chemical modification and suitability for
use as a biomaterial, particularly for introducing cell selectivity attributes [19].
1.2 Alginate
Commercially, alginates are currently extracted from marine brown algae, where they provide
a structural function as a gel in the intracellular matrix [20]. From Figure 1.1, it can be seen
that the sodium alginate structure consists of a sequence of 1,4-linked α-L-guluronic acid (G)
and β-D-mannuronic acid (M) residues, which are covalently linked and organised into blocks
of recurring MM and GG residues, as well as hybrid blocks of MG residues [21, 22]. This
sequence and composition will differ according to the type and source of the alginate being
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Figure 1.1: Molecular configuration of sodium alginate [21].
used [19, 22]. Gelation of alginates can occur through cross-linking of the alginate structure
by divalent cations, typically Ca2+. This can either take place internally, utilising an insoluble
source of calcium e.g. CaCO3, or externally through diffusion of soluble calcium ions e.g.
CaCl2 into the alginate solution [22]. The ease of chemical modifying alginate is attributed to
the availability of carboxyl and hydroxyl groups present across the polymer backbone [21].
In this thesis, the potential of an alginate fluid gel as a suitable delivery matrix and scaffold has
been explored, which would be capable of flowing under shear (enabling parenteral adminis-
tration) and ’setting’ in situ upon removal of shear forces. The definition of ’setting’, in this
context, refers to a range of viscosity values which give the gel shape maintaining properties
and result in it ceasing to flow. Therefore, this ’setting’ mechanism would not require use of
any additional chemical agents and the gel materials used have already gained FDA/EMA ap-
proval, thus allowing regulatory approval to be obtained more easily. The delivery matrix must
also be capable of maintaining the viability of a suitable cell population that has chondrogenic
potential, as well as possessing a desirable rate of degradability to ensure cells are retained at
the defect site following delivery. Here, they would then ideally facilitate chondral repair and
regeneration through the production of anti-inflammatory molecules and ECM secretion.
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CHAPTER 2
GELS AS PLATFORM TECHNOLOGIES FOR
CELL THERAPY AND DRUG DELIVERY
2.1 Hydrogels
Hydrophilic gels, also known as hydrogels or quiescent gels, are structured through the physical
or chemical cross-linking of hydrophilic polymers in the presence of an aqueous solvent, such as
water, which occupies the voids between the polymeric junctions or chain entanglements, thus
creating a three-dimensional, insoluble network [23, 24]. Hydrogels are classified as homo-,
co- or multi-polymeric, depending on the number of monomer species utilised in the reaction.
They can also be categorised according to their physical form, for example as a microsphere,
matrix or film, which is a result of the polymerisation preparation technique [25, 26, 27, 28, 29].
As previously mentioned, hydrogels can vary depending on the type of cross-linking mecha-
nism. This inherently affects their properties, as permanent junctions are formed by chemically
cross-linked polymer chains, whereas transient junctions are established through physical cross-
linking, including hydrogen bonds, ionic interactions and entanglements of polymer chains.
Therefore, further classification of hydrogels can be made according to the electrical charge
present on the polymer chains, which could be ionic, amphoteric, zwitterionic or neutral [30].
2.1.1 Range of polymers
Hydrogels can be formulated from a wide variety of polymers of synthetic or natural origin,
or even a combination of each. The advantage of synthetic polymers, e.g. poly(vinyl alcohol)
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(PVA) or poly(ethylene glycol) (PEG), is their definitive structure allowing modifications to
be made, such as adjusting their degradability or chemical and biological activity. They also
demonstrate good stability in fluctuating temperatures and have a significant water absorption
capacity, which may be as a result of their superior gel strength. However, natural polymers are
highly biocompatible and can be sourced from polypeptides or polysaccharides, e.g. hyaluronic
acid, collagen, or alginate, indicating their wide abundance and favourable biodegradation prod-
ucts, in terms of saccharide or amino acid constituents [27, 28].
2.1.2 Handling properties
When subjected to sufficient stress, hydrogels display impressive elastic behaviour, similar to
that of natural rubbers. Upon applying a minor deformation to less than one fifth of its structure,
a hydrogel is capable of quickly regaining its initial dimension, despite typically being described
as ’soft’ materials, as their elastic moduli approximately ranges from kPa to MPa [25, 26]. This
illustrates one of the limitations of hydrogels as their inferior mechanical strength, which affects
their overall handling properties [23, 29, 30, 31].
2.2 Fluid gels
Fluid gels consist of a suspension of coagulated particles, formed from a biopolymer solution
undergoing shear forces in a gelling environment [17, 18]. These shear forces are believed
to disrupt the molecular ordering process, thereby limiting the number and length of helices
formed and producing a gel that displays shear thinning behaviour. [32, 33] This is portrayed in
Figure 2.1, where molecules first associate into double helical structures or dimers through ion
bridging (represented by both ‘w’ and ‘x’), which, as in the case of alginate, later results in egg
box formation.
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Figure 2.1: Illustration modelling the various stages of fluid gel formation, as the temperature
decreases and shear forces interfere with the molecular ordering process. Molecules first asso-
ciate into double helical structures or dimers through ion bridging (‘w’ and ‘x’). Aggregation
follows (‘y’), reflecting an increase in viscosity (point ‘C’) as the temperature decreases and gel
particles form. Particles may aggregate further and coalesce (‘z’), resulting in loss of ‘hairy’
none-ordered chain fragments from particle surfaces. A significant decrease in viscosity is ob-
served on completion of conformational ordering of each hydrocolloid chain within gel particles
(‘f’ and ‘g’) after the setting temperature is reached [34].
As presented in Figure 2.2, the gelation of alginates can be described by the ‘egg-box’ model
and demonstrates how cations are able to effectively cross-link the alginate structure by em-
bedding into the crevices created through dimerisation.[34, 35] These structures then begin to
aggregate (denoted by ‘y’), reflecting an increase in viscosity (at point ‘C’) as the temperature
decreases and gel particles are formed. These particles may aggregate further and coalesce (in-
dicated by ‘z’), resulting in loss of ‘hairy’ none-ordered chain fragments from particle surfaces.
However, as previously mentioned, this process will be limited by the magnitude of the shear
field applied to the system, thus determining the final size of the gel particles. After the setting
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Figure 2.2: The ‘egg-box’ model illustrating cross-linking of poly(L-guluronate) chains in algi-
nate with Ca2+ ions [35].
temperature has been reached, a significant decrease in viscosity can be observed, which is a
consequence of completion of the conformational ordering of each hydrocolloid chain within
the gel particles (illustrated by ‘f’ and ‘g’).[34] Therefore, the key formulation parameters for
fluid gels include the rate of shear, cooling and divalent ion addition. Previous work by Streather
focused upon screening a large range of each of these parameters to determine which had the
greatest influence on the fluid gel mechanics.[36] This previous work identified a combination
of parameters that may produce an injectable formulation, that is shape maintaining upon appli-
cation and subsequent work has systematically refined those parameter values, with particular
attention to the variation of cooling rate. Furthermore, the possibility of increasing production
volume of fluid gels has been explored, in addition to the potential impact of incorporating a
solid phase within a fluid gel, in the form of alginate gel beads [37].
2.2.1 Tailoring handling properties
Viscosity
One of the key fluid-gel formulation parameters is the cooling rate, as this can greatly influence
the rheological properties of the fluid gel. This has been illustrated in previous work, which
analysed the effect of cooling rate on the viscosity of alginate fluid gels, whilst maintaining
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a constant shear rate (450s−1) [37]. However, there was insufficient control over the addition
of the cross-linking agent, calcium chloride, which is a limiting factor. Earlier studies have
demonstrated improved reproducibility of fluid gels produced at higher shear rates of 450s−1
and 700s−1, whereas lower shear rates (200s−1) can generate inhomogeneous fluid gels and
have greater variability [36]. The findings revealed that fluid gels cooled at slower cooling
rates (0.25°C min−1) were associated with lower shear-viscosity profiles (Fig. 2.3), which has
been suggested are an effect of smaller fluid gel particulates formed at reduced cooling rates, as
the shear rate dominates the formulation process. Similarly, increasing the cooling rate results
in formation of larger gel particulates, as illustrated in Fig. 2.3 by the higher shear-viscosity
profiles of fluid gels formulated at faster cooling rates [34, 37]. Although, additional work
by Gabriele et al. found that decreased cooling rates moderately increased the viscosity of κ-
carrageenan fluid gels, which they attributed to more substantial bridging of gel particulates, as
they have more time to develop. They also discovered that the structure of fluid gels is subject
to additional "strengthening" post-formulation and occurs most prominently in gels produced
at faster cooling rates. However, the sample volumes (1250µL) studied and lower shear rates
(50s−1, 100s−1 and 300s−1) used to manufacture the fluid gels limited the significance of the
study [37, 38].
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Figure 2.3: The effect of cooling rate on the mechanical properties of 1% alginate fluid gels,
with an initial production volume of 20ml and 0.1M CaCl2 addition [37].
In order to put the shear-viscosity response of alginate fluid gels, cooled at varying rates, into
context, they were compared to those of deionised water (DI H20), glycerol and toothpaste (Fig.
2.4). This helped illustrate the shear thinning behaviour of toothpaste, though at significantly
higher measured values of viscosity than those evaluated for fluid gels produced at the specified
cooling rates.
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Figure 2.4: Evaluation of the shear-viscosity profiles of toothpaste, glycerol and DI H2O, when
compared with 1% alginate fluid gels produced at different cooling rates [37].
Biodegradability
Experimental studies on the biodegradability of gels have been carried out since 1947, where
initial work on alginate dressings by Blaine revealed its complete absorption by animal tissues,
which was dependent upon the concentration of the cross linking agent, such as calcium chlo-
ride, or the sodium alginate concentration (3% and 5%). Additionally, the physical structure
and form of the gel also had an influence on its rate of absorption, though overall the immune
response was negligible [39]. Subsequent work determined that the vascularity of the tissue af-
fected the rate of absorption as well, and alginates with synthetically increased sodium ion con-
tent were absorbed much more quickly than those with higher calcium ion content [40]. This is
in agreement with more recent findings investigating the distribution of alginate-tyrosinamide in
male Wistar rats, following systemic and subcutaneous administration, which indicated the de-
pendence on polymer molecular weight, as fractions of low molecular weight (≤ 48,000 counts
per minute) were removed in the urine, whilst fractions of larger molecular weight resided in
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the circulatory system, but without any tissue accumulation. This was suggested to result from
the ability of the former to attain clearance by the lymphatic system and furthermore, delivery
subcutaneously ensured approximately 70% retention at the application site [41]. There are
also fewer reaction locations in higher molecular weight polymers, limiting the opportunity for
hydrolysis and reducing the rate at which degradation can take place [42].
These preliminary investigations were crucial for the development of the alginate fibre dressing,
Sorbsan, which easily undergoes biodegradation in wounds, so that removal is unnecessary and
allows granulation tissue to be formed. This product has demonstrated successful application
in treating trophic and diabetic ulcers that can become infected and inflamed, thus prolonging
the healing process [43]. Thereafter, it was shown to minimise blood loss at skin graft donor
sites, indicating considerable haemostat efficacy. These biodegradable properties of calcium
alginate are attributed to its conversion into sodium alginate, thereby inhibiting the accumula-
tion of residual material in the wound due to its solubility in bodily fluids [44, 45]. Similar
observations were made by Stoichet et al., who studied the stability of cell-encapsulating al-
ginate and agarose hydrogels in vitro. Their work illustrated a reduction in the strength of
alginate gel over a 3-week period, implicating the diffusion of calcium ions from the matrix and
causing decrosslinking of the structure. This allowed improved permeation of ovalbumin and
BSA and highlighted the importance of controlling biodegradation, particularly for gels that
require mechanical functionality, such as those intended for use in orthopaedic implants [46].
Ideally, it would be desirable to tailor the rate of polymer degradation in parallel with the rate
of tissue growth, which has led the examination of appropriate methods and techniques that
can help achieve this [15]. These include periodate oxidation of biopolymers, such as sodium
alginate, which, following incorporation with chondrocyte cells, enabled the formation of new
cartilage-like tissue in SCID mice. In comparison to unmodified alginate, its partially oxidised
configuration improved its biodegradabillity in vivo| over 7 weeks, whereas localised regions
of cartilage like-tissue growth appeared to be restricted by substantial amounts of unmodified
alginate residue, which they reported was consistent with previous findings [47]. In addition to
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periodate oxidation, other alternative procedures that can enhance the rate of biodegradation in-
clude irradiation or utilisation of the enzyme, alginate lyase, which respectively cleave covalent
and glycosidic bonds throughout the polymer. These have both been employed in the formu-
lation of a biodegradable alginate matrix for the encapsulation of isolated ovarian cells, which
were successfully implemented in vitro and in vivo. However, prior to this, they noticed no dif-
ference in the rigidity or size of untreated alginate beads, following one week of in vitro culture
with isolated preantral follicles. Therefore, they were able to conclude that the biodegradation
of the alginate scaffold enabled the infiltration of cells and vascularisation in vivo, potentially
promoting the expansion and longevity of the encapsulated ovarian cells. This has promising
applications for restoring endocrine activity and fertility in cancer patients, where, after disease
remission, transplantation of cryopreserved ovarian tissue is not advised, so the development of
a biodegradable artificial ovary could enable survival and growth of isolated follicles and ovar-
ian cells [42, 48, 49, 50]. Analogous results were also described in earlier literature by Alsberg
et al. and Simmons et al., who analysed the effects of alginate hydrogel scaffold degradation
on the formation of bone tissue. Using γ-irradiation, they were able to regulate the biodegrad-
ability of alginate, with irradiated samples supporting faster synthesis of mechanically superior
osseous tissue. As previously mentioned, this is has been confirmed to occur from an acceler-
ated transfer of divalent calcium ions with monovalent cations, including potassium, phosphate
and sodium, which may be distributed throughout the medium encompassing the alginate hy-
drogel. Remarkably, alginate gel samples used to encapsulate fibroblast cells were able to
maintain their shape and self-supporting structure over a 4-week period, despite experiencing
an increased degradation rate over the first week [51]. These studies also helped to determine
sufficient levels of radiation dosage, as it is crucial that biopolymers undergo degradation at an
appropriate rate that can still sustain cell proliferation and provide support in vacuous defects
[49, 52, 53]. Another process that has been utilised for enhanced biodegradability is adjustment
of the molecular weight distribution in alginate polymer chains, which preserved the mechani-
cal behaviour and elastic moduli of gels, as well as facilitate bone growth through the delivery
and stimulation of bone marrow stromal cells (BMSCs). This was accomplished through oxida-
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tion with sodium periodate and γ-irradiation in order to modify the chemical composition and
molecular weight of alginates with different molecular weights [54, 55].
Comparatively, studies have examined the biodegradable properties of gellan gum, specifically
demonstrating its capability in vitro. Results from work by Lee et al., suggested that the acyl
content may influence its degradation, as low acyl gellan gum displayed greater stability than
blends of low/high acyl gellan gum, with higher ratios of high acyl gellan gum exhibiting faster
rates of degradation. They theorised that the presence of a large acyl group on the 1,3-β-D-
glucose might limit the configuration of tightly bound helices and hence, affect the gel stability.
Therefore, they concluded that applications of low acyl gellan gum (2% w/v) may be suit-
able for musculoskeletal tissue regeneration, allowing matrix reconstruction to transpire over
longer periods of time and also, considering its superior compressive modulus [56]. Additional
experiments have measured the degradability of low acyl gellan gum (1% w/v) against other
potential biopolymers, sodium alginate (2% w/v) and low methoxy (LM) pectin (2% w/v), fol-
lowing seeding with rat BMSCs. Interestingly, the data showed great variations between each
polysaccharide, particularly for the alginate hydrogels, which degraded to 20% of their original
modulus by day 7, whereas gellan gel hydrogels took over 28 days to reach this value. This was
explained, as previously mentioned, due to the initial exchange of critical ions and restructuring
of the alginate gel matrix, after which there is a decrease in the rate of degradation. Furthermore,
deposition of mineral by differentiated rBMSCs may have induced calcium chelation, known to
originate from organic phosphate components. However, the validity of this research is appli-
cable to low viscosity (20-40 cps) sodium alginate and gel testing is limited to its relevance in
vitro [57, 58]. It appears that there is insufficient evidence surrounding the degradability of gel-
lan gum in vivo, although some preliminary investigations have been made, they have declared
the need for further analysis to gain an understanding of its mechanism of degradation [59, 60].
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pH response
Another factor that can influence the biodegradability of polymeric hydrogels is the pH of the
environment, which varies depending on the location of the tissue within the body and also, on
whether it is in a healthy or diseased condition. For example, the stomach features the most
acidic domain, with a pH range of 1.0 to 3.0, whilst the pH of a wound or inflamed tissue can
fluctuate from as much as 5.45 to 8.65. This can significantly impact the structure and integrity
of a gel, as it is inclined to swell when exposed to a pH less than or greater than its pKa value,
dependent upon the cationic or ionic nature of the polymer, respectively. These mechanical
properties have so far been exploited in the field of drug delivery, as they offer considerable
advantages for targeted therapies, including treatment for intestinal diseases or malignant tu-
mours. Specifically, protein molecules, such as insulin, have been incorporated into hydrogel
networks, utilising the polycationic copolymer, chitosan, with a pKa of approximately 6.3. This
would therefore enable oral delivery of insulin, as the hydrogel structure would be maintained
and hence, protect the therapeutic protein until it passed into the stomach, where the amino
groups on the polymer chain would then become ionised, causing electrostatic repulsion. Con-
sequently, the hydrogel would become swollen, creating a more porous network and also, al-
lowing the insulin to elute out into the surrounding environment [25, 61, 62, 63, 64]. In addition
to this, this technology has also exhibited its anticancer therapeutic potential, as extracellular
tumours can be distinguished by their slightly acidic climate (pH 6.5-7.2) [61, 63, 65].
Until recently, the focus of this work had centred around quiescent gels, but current examination
by Bradbeer et al. has explored the effects of subjecting low acyl gellan gum fluid gels to a
selection of acidic pH values. The results of this research have demonstrated that even minimal
acid exposure (around 1 hour in duration) can enhance the strength of gellan fluid gels, to the
point of solidification, as it seems to reinforce the preexisting cross-linked biopolymer structure
and has previously been confirmed in similar antecedent studies. Additionally, comparable
observations have been made for alginate gels and consequently, may indicate the suitability of
these polysaccharides for inclusion in the treatment of osteochondral or osseous tissue defects,
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which, as previously mentioned, can be associated with a reduced pH due to local inflammation
[17, 66, 67, 68, 69].
Biochemistry/Cell viability
As previously mentioned, alginate hydrogels have been successfully employed in the encap-
sulation of fibroblast cells, with demonstrated cell viability over 60 days, irrespective of gel
concentration [51]. Moreover, viability was maintained for a further 90 days, which may be
attributed to the vastly hydrated morphology of hydrogels, comparable in structure to the extra-
cellular matrix (ECM), that can facilitate perfusion of nutrients and waste products, as well as
support paracrine signalling [70, 71, 72]. However, the metabolic activity and proliferation of
these cells was found to be suppressed by the mechanically confining architecture of the hydro-
gel and subsequent work has also elicited the lack of ECM deposition by cells encapsulated in
hydrogel substrates, which is essential for tissue regeneration [72, 73]. Therefore, this prompts
consideration of cells that are responsive to their physical and chemical environment, such as
mesenchymal stem cells, whose differentiation pathways can be significantly influenced by fac-
tors such as the porosity and stiffness of the matrix. In particular, they are extremely sensitive
to the elastic properties of the material, which suggests that encapsulation of these cells within
hydrophilic gels may result in their inadvertent differentiation due to imposition of external
forces [74]. Alternatively, investigations have been made into the use of fluid gel scaffolds for
cellular delivery, which enable the suspension of cells between the interstices within the liquid
component of the fluid gel system, without changing the basic composition of the gel. Addition-
ally, Paxton et al. have established excellent cell viability of MC-3T3 cells within 1% agarose
fluid gels over a 24 h period, although agarose itself may be unsuitable for tissue regeneration
applications owing to its non-degradable qualities [70, 75].
Temperature response
In consideration of therapeutic applications for gels, a significant factor that could affect their
stability in vivo is the physiological temperature of the body. Though this would not occur in
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isolation, but in conjunction with the impact of shear force, which together can deteriorate the
mechanical properties of the gel. As illustrated in Figure 2.5, the yield stress of the gel can shift
as a function of temperature, which, for alginate fluid gels, indicates a decrease in its initial
viscosity at 37°C [36].
Figure 2.5: The variation between the storage (G’) and loss (G”) moduli of 1% alginate fluid
gels at 25°C and 37°C, formulated with 0.1M CaCl2 [36].
These effects may also have implications for gel sterilisation procedures, as processes such
as autoclaving can utilise temperatures in excess of 120°C, causing decomposition of the gel
structure. For sodium alginate gels (1% and 3%) crosslinked with 0.1M CaCl2, this is a result of
depolymerisation and is more discernible in gels of greater molecular weight or higher polymer
concentration. This is believed to be synonymous across other biopolymer materials and may
be seen as a consequence of entropic dominance, forcing the expulsion of water from the gel
and hence, collapse of its supportive infrastructure [61, 76, 77]. However, reduction of the
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sterilisation temperature has been correlated with a lower deficit in gel stability[78, 76, 77].
Furthermore, it is possible to minimise the degree of depolymerisation through autoclaving
by increasing the pH value of the alginate solution to pH 7.0-8.0. [45, 79]. Alternatively,
steam sterilisation has been established as a more feasible substitute, particularly for gellan




BONE MARROW ASPIRATE CONCENTRATE
(BMAC): EXISTING AND POTENTIAL METHODS
OF DELIVERY
3.1 Bone Marrow Aspirate Concentrate (BMAC)
Bone Marrow Aspirate Concentrate (BMAC) consists of a heterogeneous population of cells,
predominantly neutrophils and erythroblasts, but also includes lymphocytes, eosinophils, mono-
cytes and basophils. Of the mono-nucleated cells, bone marrow-derived MSCs (BM-MSCs) ac-
count for a mere 0.001 to 0.1%, with the remaining volume of BMAC being made up of a vast
number of platelets, growth factors and cytokines, which are inter-related [81, 82, 83, 84, 85].
Currently, there is steadily growing interest in the application of BMAC for cartilage repair and
regeneration, owing to promising results obtained in small and large animal models, as well as
initial human trials [81, 86]. This has included evidence of hyaline like cartilage production,
without any reported adverse events or harvest site morbidity [81]. However, additional inter-
est has been expressed in platelet-rich plasma (PRP), which has also indicated positive treat-
ment outcomes in cartilage defect repair, including enhanced joint function [81, 87]. Through
the centrifugation of peripheral blood, PRP is associated with a supraphysiological number of
platelets that contain a large concentration and variety of growth factors. Consequently, these
can help stimulate local angiogenesis and modulate the inflammatory effects of tissue damage,
amongst numerous other functions [87, 88]. Owing to their similarity in composition, BMAC
has actually been described as PRP with the exception of an additional stem cell population
[87]. Although, after analysing the cellular composition and cytokine concentrations of both
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BMAC and PRP, it was found that BMAC encompassed approximately 2.5 times the platelet
concentration of PRP, as well as almost 12 and 20 times the number of white blood cells and
neutrophils, respectively. Potentially resulting from this higher concentration of platelets, the
average concentration of growth factors and cytokines, such as vascular endothelial growth fac-
tor (VEGF), interleukin-8 (IL-8) and transforming growth factor-β2 (TGF-β2), was markedly
greater in BMAC than PRP, as these reside within the alpha granules of platelets [81, 87].
Considering this composition in further detail, it is clear that the positive clinical findings of
utilising BMAC in the treatment of cartilage defects are supported by the underpinning bio-
logical actions of some of these growth factors. In particular, IL-8 has been found to encour-
age migration of BM-derived cells, such as MSCs, to the defect site and also augment VEGF
production, thus improving angiogenesis that is essential for epiphyseal vascular supply and
cartilage regeneration [81, 89]. Perhaps more prominently recognised is the TGF superfamily
that comprises TGF-β1, TGF-β2, TGF-β3, along with BMP-2 and BMP-7. All of which are
required in a cascade of pathways that ultimately lead to chondrogenesis and chondrocyte ex-
pansion [81, 90]. Specifically, TGF-β2 has shown greater efficacy in promoting chondrogenesis
than TGF-β1, though it acts synergistically with BMP-2 to stimulate chondrogenic differenti-
ation of MSCs in vitro [81, 91]. BMP-7 also has an important role to play in cartilage tissue
formation, as it can enhance extracellular matrix production and seems unique in its ability to
remain unaffected by common debilitating factors, such as age [81, 90]. Other mentionable
growth factors that are likely contributing to its success in human and animal models include
insulin-like growth factor (IGF-1) and the family of fibroblast growth factors (FGF), which are
associated with elevated collagen and proteoglycan synthesis and improved BMP signalling,
leading to greater and earlier differentiation of MSCs, respectively [81, 92, 93, 94, 95, 96].
BMAC is primarily obtained through aspiration of bone marrow from the iliac crest, as this
has been reported to contain, on average, higher concentrations of MSCs [83]. Although, it is
still uncertain as to the clinically effective quantity of MSCs that would be required for cartilage
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repair [87]. Following aspiration, the BMAC is then heparinised and filtered, before being con-
centrated through the use of a commercially available system, typically the Harvest BMAC®
SmartPrep2®, which has been shown to be superior in isolating greater numbers of progenitor
cells [97, 98].
3.2 Existing and potential methods of delivery
The ability to collect the aspirate and combine it with a delivery matrix at the patient bedside,
potentially circumvents the need of having to extract a cell population and expand them off-
site before reintroducing them into the patient at a later date. There are currently a number
of existing scaffolds that could and have been used to support the structure of BMAC and in
some cases, form a clot to stabilise and enable its delivery in the form of an implant. The most
promising of which is a chitosan-based product, known as BST-CarGel®, which was designed
to be combined with a patient’s whole blood before being injected into their cartilage defect.
BST-CarGel® is successful in that it is capable of producing a physically stable and injectable
implant, with demonstrated cell viability of BMAC until natural clot degradation, thus proving
its suitability as a one-stage cell based treatment [97, 99, 100]. However, its efficacy and appli-
cation with BMAC has yet to be established in in vivo studies and it is not appropriate for all
defects [99, 100, 101].
Other potential scaffolds that are commercially available include Chondro-Gide and Alpha
Chondro Shield. Chondro-Gide is formed of naturally occuring type I and type III collagen,
arranged in a bilayered structure, featuring both a porous surface and a compact surface that
enables cell adhesion and inhibits cell effluence, respectively. This creates a strong and resilient
scaffold that has received extensive clinical application in autologous matrix induced chondro-
genesis (AMIC) operations and autologous chondrocyte implantation (ACI), however it does
require fixation within defects using either suturing or fibrin glue [102, 103, 104, 105, 106].
In contrast, Alpha Chondro Shield comprises a synthetic, non-woven homogeneous network
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of polyglycolic acid (PGA) fibres, which was designed for use with microfracture treatments
for simple, practical and off-the-shelf application. Although, to date, there has been no clinical
evidence published regarding its use with MSCs or chondrocytes and furthermore, in vitro data
comparing chondrogenic differentiation and culture of BM-MSCs and adipose tissue-derived
MSCs (AT-MSCs), indicates that the fast degrading PGA fibres in Alpha Chondro Shield fail
to support cell growth and proliferation. Additionally, it has been suggested that PGA based
biomaterials may be susceptible to release acidic degradation products throughout long term
culture, which would clearly impede cell proliferation [102, 103].
In work by Kohli et al., Chondro Gide and Alpha Chondro Shield were examined along with
with a third clinical grade scaffold, Hyalofast™, which is composed of a non-woven, naturally
occurring hyaluronic acid-based membrane, for the original purpose of treating chondral and
osteochondral defects by ensnaring MSCs in situ. This scaffold has demonstrated both adherent
and malleable properties, when combined with BMAC for clinical repair, as well as promising
results after 2 years follow up. However, following in vitro analysis, it was revealed that its
structure deteriorated in long term culture and poor cell retention was observed. Though, this
highlights a clear barrier between bench-to-bedside translation, since in vitro studies can not
effectively mimic the conditions and environment that exist in vivo [102, 103, 107]. Similarly,
another hyaluronic acid-based scaffold, Hyalograft C® has contributed to the production of pri-
marily hyaline-like cartilage repair tissue in recent clinical trials, when used in conjunction
with autologous chondrocyte implantation. Its structure is also fabricated from a matrix of 20-
µm-thick fibres, creating a porous network with varying sized interstices. Although, in 2013,
the European Medical Association (EMA) made the decision to remove Hyalograft C from the
European market, after reporting concerns surrounding their manufacturing processes and the
standard of evidence that they presented for approval [102, 108, 106, 109].
One can therefore infer some common features and characteristics that are essential for an opti-
mum delivery vehicle that will sustain a population of cells and provide the correct biochemical
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microenvironment to direct their lineage down a chondrogenic or osteogenic route. From the
aforementioned case studies that have been discussed, it seems beneficial to utilise natural ma-
terials that have good biocompatibility, with particular preference being given to collagen and
hyaluronic acid, as a consequence of their native presence in cartilage tissue [102]. Ideally,
the scaffold would also be biodegradable at a rate that will enable simultaneous regeneration
of the tissue, possibly through facilitating extracellular matrix production by autologous cells,
whilst avoiding generation of concentrated acids or debris that could cause local inflammation
and apoptosis [102, 106, 101]. As a result, the structure of the implant would need to have
suitable porosity to allow migration of cells, growth factors and cytokines in vivo, but would
additionally require appropriate stiffness and mechanical properties, as this influences MSC
differentiation [102, 110]. Furthermore, this property would determine its ability to maintain
stability in situ, particularly if the delivery vehicle possesses fluidity upon application, which
would be desirable to accommodate injectable treatment with the scaffold. By formulating such
a implant, one can also satisfy fitting a variety of shapes and forms associated with cartilage
defects, as the architecture would be able to conform to the nature of the defect. Evidently, a
tissue-adhesive quality may be favourable, as it was previously mentioned that many scaffolds
require the use of sutures or biological or synthetic glues in order to ensure that they are retained
in the defect. BST-Cargel is unique, however, in that it possesses this characteristic as a result
of its polycationic nature [102, 101, 99]. Another advantage of BST-Cargel is its physiological
pH compatibility, as well as its excellent viscosity profile that enables it to mix homogeneously
with whole blood or BMAC and subsequently form a stabilised blood clot within a 15 minute
clotting timeframe. This therefore permits an ideal, minimally invasive, single step administra-
tion of the scaffold for cartilage repair [101, 99, 97].
Finally, a delivery vehicle that is reproducible, economical and can support differentiation and
integration of cells in vivo, is evidently the ultimate ambition for scaffold design [83, 106].
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CHAPTER 4
RESULTS CHAPTER 1: FORMULATION OF
SHEAR-THINNING GEL SYSTEM AND CELL
VIABILITY WITHIN FLUID GELS
As previously discussed (Chapters 1, 2 and 3), a suitable delivery matrix would possess fluidity
upon application in order to accommodate parenteral administration and would ideally ’set’ in
situ upon removal of shear forces, without the use of any additional chemical agents. Further-
more, the significance of maintaining cell viability was also considered, leading to the conduct
of the following experiments.
4.1 Materials and Methods
4.1.1 Materials
The following materials were purchased from Sigma-Aldrich: Anhydrous calcium chloride
(CaCl2, 110.98g/mol, C1016), ≥93%, granular ≤ 7mm; Alginic acid sodium salt (NaC6H7O6)
powder (180947) and medium viscosity from brown algae (A2033) and Dulbecco’s phosphate
buffered saline (PBS) (D8537). DI H20 was obtained from Biochemical Engineering laboratory
G13.
Preparation of sample materials
A 500ml 1M calcium chloride solution was prepared by dissolving 55.49g of CaCl2 in DI H20.
This was then used to obtain a diluted 100ml 0.1M calcium chloride solution. For production of
alginate fluid gels, 1% and 2% alginate solutions were made using a magnetic hot plate stirrer
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(set to 400rpm) to dissolve 1g and 2g, respectively, of alginic acid sodium salt in 100ml of
DI H20 (heated to 60°C) over a 2 hour period. A Kern (Germany) 440-35N mass balance and
Ohaus Pioneer PA114 analytical balance were used to weigh out all sample materials.
Formulation of alginate fluid gels
Formulation of fluid gels and shear testing were carried out using a TA Instruments AR-G2
Rheometer (9B4032), with a temperature-controlled concentric cylinder (4000µm gap) and
14mm four-blade vaned rotor geometry (993058). The system was self-calibrated through ro-
tational mapping of the connected geometry and between experiments, the cylinder and vaned
rotor were detached and cleaned using DI H20. This was operated with a compressed air sup-
ply (40psi) and Julabo water bath (FP35), in conjunction with Rheology Advantage Instrument
Control AR and Rheology Advantage Data Analysis software. A procedure file was created
with the following specification:
– Test type: Temperature ramp
– From: 60°C to 30°C
– Wait for start temperature: V
– Ramp rate: 1.5°C min−1
– Sample points: 20
– Controlled variable: Shear rate: 450 s−1
Additionally, fluid gels were produced using a Peak hold ramp, with the following specification:
– Step name: Conditioning step
– Initial temperature: 20.0°C
– Wait for correct temperature: Yes
– Do set temperature: Yes
– Wait for normal force: No
– Perform pre-shear: No
– Perform equilibration Yes
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– Equilibration duration: 0:01:00 (hh:mm:ss)
– Wait for zero velocity: No
– Control normal force: Uses current instrument settings
– Purge gas only: No
– Step name: Peak hold step
– Test type: Peak hold ramp
– Controlled variable: Shear rate: 500 s−1
– Duration: 0:30:00 (hh:mm:ss)
– Delay time: 0:00:00 (hh:mm:ss)
– Temperature: 20.0°C
– Wait for start temperature: No
– Motor mode: auto
Initially, 18ml volumes (± 0.02ml) of 1% alginate solution were added into the concentric
cylinder by pipette, followed by 2ml (± 0.02ml) volumes of 0.1M CaCl2 solution, heated to
60°C (± 1.0°C). The CaCl2 solution was added manually in a dropwise manner the righthand
side of the cylinder, as soon as the temperature ramp was initiated at 60°C. Subsequently, 27ml
(± 0.03ml) and 3ml (± 0.03ml) volumes of 2% alginate and 0.1M CaCl2 solution were used,
respectively.
Rheological testing - Strain and frequency sweeps
Since fluid gels exhibit viscoelastic behaviour, they can be described in terms of their viscous
and elastic components; their storage modulus (G’) and loss modulus (G”), respectively, since
the elastic response of the material represents the energy stored during the deformation process
and the viscous response represents the energy lost through heat during deformation. Conse-
quently, materials with a higher G’ than G” exhibit more solid like behaviour and those with
a greater G” than G’ behave more as a liquid [111, 112]. These viscoelastic properties can ei-
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ther be established using dynamic or transient testing, however the latter, which includes stress
relaxation and creep testing, is limited by the fact that the behaviour of the material cannot be
described in terms of the frequency. Therefore, for the purpose of this study dynamic testing
was used to obtain all rheological measurements. These types of test involve the application of a
small sinusoidal strain (γ) (or stress (σ)), whilst simultaneously measuring the stress (or strain)




where G’ and G” are both functions of the angular frequency, ω [111].
Following formulation, rheological tests were performed on fluid gels using an ARG2 Rheome-
ter (TA Instruments) with two 40mm stainless steel sandblasted parallel plates (AC20-3 Cover
Plate and 993244, TA Instruments) in order to prevent slippage. Strain sweeps were performed
to determine the Linear Viscoelastic Region (LVR) of the fluid gels, in which the stress is in-
dependent of the strain [112]. Accordingly, an oscillation procedure file was created, using a
constant frequency of 1.0 Hz, at 37°C, in a strain range of 0.1 - 500%. Frequency sweeps were
also performed as part of the oscillation procedure, using a frequency range of 0.1 - 100.0 Hz,
at 37°C, at a fixed strain of 0.5%.
4.1.2 Cell culture
MC3T3 fibroblasts were obtained from the American Type Culture Collection (ATCC) and cul-
tured in high-glucose Dulbecco‘s modified Eagle‘s medium (DMEM) supplemented with 10%
Fetal Bovine Serum (FBS) (Sigma-Aldrich F7524, UK) and 1%vol Penicillin/Streptomycin
(P4333-100ml Sigma-Aldrich, UK). The culture medium was exchanged every two or three
days and cells were incubated in a 5% CO2 incubator at 37°C.
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4.1.3 Fibroblast suspension within alginate fluid gels
1% and 2% w/v medium viscosity sodium alginate fluid gels, produced as described in 4.1, were
exposed to UV-irradiation within a sterile biosafety cabinet, with laminar flow, for a minimum
of 30 minutes, prior to suspension of MC3T3 fibroblasts and culture within Petri dishes.
4.1.4 Live/dead staining
Cell viability was analysed qualitatively using calcein AM and propidium iodide staining. Im-
ages of stained cells were then captured using confocal laser scanning microscopy (Olympus
FV1000, Multiple Ar laser, Germany).
4.2 Results and discussion
4.2.1 Characterising fluid gels in terms of their rheological profile
Fluid gels were characterised in terms in of their rheological profile, using methods outlined
in 4.1.1. This measured the storage modulus (G’), loss modulus (G”) and complex viscosity
(η∗) of 2% alginate fluid gels at 37°C, in order to simulate their mechanical behaviour in vivo.
After conducting strain sweep testing, the LVR was determined as below 10% strain. Therefore,
frequency sweep testing was performed in this range, at 0.5% strain, which was consistent with
previous studies [32, 113, 114].
Previous work had been conducted on 2% alginate fluid gels formulated using a temperature
ramp from 60°- 30°C, however an original study conducted by Streather described the produc-
tion of alginate fluid gels using a slightly more extensive temperature ramp, from 60°- 25°C
[37, 36]. Therefore, 2% alginate fluid gels using three different formulation procedures were






































Figure 4.1: The variation between the storage (G’) and loss (G”) moduli and the resulting
complex viscosity of 2% alginate fluid gels at 37°C, formulated with 0.1M CaCl2 using a tem-
perature ramp from 60°- 25°C.
For 2% alginate fluid gels formulated using a temperature ramp from 60°- 25°C, the dominance
of the storage modulus (G’) over the loss modulus (G”) was seen for up to a frequency of almost
65 Hz, when the fluid gel would behave more as a liquid and is confirmed by the decrease in the
complex viscosity (η∗) (Fig. 4.1). Up to this frequency, the storage modulus was recorded as
approximately 120 Pa, which was slightly higher than what had been measured previously for
2% alginate fluid gels that were produced using a pin stirrer method [115].
A similar profile was seen for 2% alginate fluid gels formulated with a temperature ramp from
60°- 30°C ,(Fig. 4.2), after 24 hours post-formulation. However, up to the frequency of approx-
imately 65 Hz, the storage modulus was measured at around 202 Pa, remarkably higher than
was recorded for the 60°- 25°C formulation. Although, this measurement was then repeated
following a further 24 hours and it was found to have to reduced by almost 10% to 185 Pa,































































































(b) 48 hours post-formulation
Figure 4.2: The variation between the storage (G’) and loss (G”) moduli and the resulting
complex viscosity of 2% alginate fluid gels at 37°C, (a) 24 hours post-formulation with 0.1M






























































































(b) 48 hours post-formulation
Figure 4.3: The variation between the storage (G’) and loss (G”) moduli and the resulting
complex viscosity of 2% alginate fluid gels at 37°C, (a) 24 hours post-formulation with 0.1M
CaCl2 (b) 48 hours post-formulation, using a peak hold ramp at 20°C and a constant shear rate
of 500 s−1.
This was also the case for 2% alginate fluid gels produced using a isothermal peak hold ramp
at 500s−1. As illustrated in Figure 4.3, there was a 20% reduction in the storage modulus at
the same frequency of approximately 65 Hz, after 48 hours post-formulation. Though, the peak
hold procedure used may be preferential over the temperature ramp profiles, since the storage
modulus recorded up to this frequency was much greater, at 324 Pa.
In the case of all three formulations for alginate fluid gels, the frequency sweep analysis char-
acterised uniform gel-like behaviour across the frequency range considered, correlating with
previous work [115]. This has formerly been described on a scale between a ‘weak gel’ and a
‘strong gel’ with regards to the relationship between the frequency and G’ and G”. The nature
of the ‘elastic’ and ‘hairy’, ‘strong gel’ particulates; enabling the formation of a loose network
and structure within the fluid gel, combined with the ‘weak gel’ configuration; permitting the
flow of this network under shear, is what distinguishes the fluid gel microstructure from other
types of gel [32, 115]. For each of the formulations discussed, there were seemingly gradual
increases in the elastic component of the fluid gels, in terms of their storage modulus, G’, up
to the point where the viscous element, measured by G”, began to dominate. This further illus-
trates the resistance of polymer structure to an applied force, quintessential to that of an elastic
material.
4.2.2 Tailoring formulation processing parameters for different applica-
tions
As previously shown in 2.2.1, from Figure 2.3, it is clear that the resting properties of fluid
gels can also be modulated by adjusting the cooling rate of the formulation, as this affects the
initial viscosity of the system under essentially zero shear force. This would allow very fine
control over the resting viscosity for low viscosity ranges from approximately 4 - 13 Pa.s. In
order to increase the initial viscosity, the weight percentage of the polymer must be increased.
This has been established by the data given in Figure 4.4, which demonstrates that by increasing
the weight percentage of the polymer by 1% to 2%, whilst observing the same cooling rate, a
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fluid gel with an initial viscosity of around 37 Pa.s can be fabricated that is quite strongly shape
maintaining and therefore, relatively stiff in nature. The significance of this work highlights the
different applications that would suitable for each type of gel, based on its resting properties.
For example, a 1% fluid gel, with a lower initial viscosity, could be useful for topical applica-
tion, potentially as a skin cream that would permit spreading, but would not necessarily require
mechanical stiffness or a high resting viscosity, as it would not need to endure significant pres-
sure. However, it might be less appropriate to utilise this gel in orthopaedic applications, in load
bearing joints, as the gel may be susceptible to seepage from the defect, or in an articulating
joint, it could be subject to a constant degree of shear from the joint space, which may prevent
the gel from regaining its initial viscosity. In this case, a fluid gel with a higher resting viscosity
would be more applicable, which would be capable of tolerating higher rates of shear force.
Consistent with earlier work that has explored the mechanical spectra of alginate fluid gels
as a function of polymer concentration, the 2% alginate fluid gel system exhibited a greater
shear-viscosity profile under shear compared to the 1% fluid gel system, as illustrated in Figure
4.4 [115]. Although, whilst both formulations demonstrated injectable properties, the increased
viscosity of the 2% gel system showed greater retention within model defects and improved self-
setting ability (Fig. 4.5). This would be more significant in clinical practice, where minimal

































1% alginate - 1.5°C/min
2% alginate - 1.5°C/min
Figure 4.4: The rheological profile difference between 1% and 2% alginate fluid gels, with an
initial production volume of 30ml and 0.1M CaCl2 addition, formulated at 1.5°C cooling rate.
34
(a) Injectable application (b) Post application
(c) Pre-inversion (d) Mid-inversion
(e) Mid-inversion (f) Post-inversion
Figure 4.5: Still frames demonstrating injectable application of 2% alginate fluid gel and bead
system into model cartilage defect, with alginate beads dyed red for clarity.
4.2.3 Visualisation of the fluid gel structure
As an acidic polysaccharide, fluid gels manufactured using sodium alginic acid are susceptible
to staining by the cationic dye Alcian blue, through what is thought to be the establishment
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of salt linkages with the acidic groups of anionic polymers [116]. This has been illustrated in
Figures 4.6 and 4.7 that reveal an alignment of strands or fibres in the fluid gel microstructure,
which may contribute to its mechanical properties, which were originally thought to result from
the network of fluid gel particulates formed through conformational ordering of hydrocolloid
chains [37]. These optical micrographs of 2% alginate fluid gels are substantially clearer and
enable more discerning features to be elicited than images previously taken for 3% alginate
and 2% kappa-carrageenan fluid gels, following their dilution with deionised water [38, 115].
Similar findings have recently been discovered with fluid gels manufactured using gellan gum,
therefore future work will include further characterisation of the fluid gel microstucture, through
both phase contrast and confocal microscopy by fluorescently labelling the alginate biopolymer.
Figure 4.6: Alcian blue staining of 2% medium viscosity alginate fluid gels, formulated using
(A) 60-25°C and (C) 60-30°C temperature profiles, for identification and visualisation of their
microstructure on (B) glass slides.
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Figure 4.7: Brightfield images illustrating microstructure of 2% medium viscosity alginate fluid
gels stained with alcian blue and imaged on two different focal planes ((A) and (C)), overlapping
in (B) (magnification x10).
4.2.4 Live/dead staining of MC3T3 fibroblasts within alginate fluid gels
Following formulation and characterisation of the fluid gel microstructure, recent efforts were
made to evaluate the viability of a MC3T3 fibroblast cell population within 1% and 2% alginate
fluid gels. Initial results have provided promising evidence, with a large proportion of the
population expressing excellent viability after 7 days in culture and no significant fibroblast
death was observed (Fig. 4.8).
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Figure 4.8: Calcein-AM/PI live/dead staining of MC3T3 fibroblasts in 2% w/v alginate fluid gel,
cross-linked with 0.1M CaCl2, after 7 days. Live and dead cells stain green and red, respectively,
with the majority of cells remaining viable following 7 days of culture within the fluid gel matrix
and no significant fibroblast death observed.
4.2.5 Live/dead staining of BMAC cells
Further work has now been conducted with human BMAC, which was combined with the fluid
gel material within quadrant Petri dishes. This was subsequently visualised using Calcein-
AM/PI live/dead staining to assess the viability and distribution of cells within the matrix,
which can be seen in Figure 4.9. Overall, the cells seem to express good viability following
incorporation with the gel scaffold, though some apoptotic cells can be observed, but would be
anticipated for primary human cell culture, as they are generally more fragile and sensitive to
their environment. It was therefore necessary to attempt to sterilise the fluid gel material prior
to combination with the BMAC, as it is currently not manufactured under sterile conditions.
Consequently, for this preliminary work, small volumes of the gel were placed in shallow petri
dishes and exposed to UV-irradiation within a sterile biosafety cabinet, with laminar flow, for a
minimum of 30 minutes. However, whilst this sterilisation procedure is beneficial for preserv-
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ing the mechanical properties of the gel, it cannot sufficiently eliminate the presence of bacteria
in alginate gel samples that have previously been contaminated with E. coli, as it is largely
dependent on the thickness of the material and its ability to absorb the specific wavelength of
the light. Thus, this can help explain the ultimate infection of the BMAC samples incorpo-
rated into the alginate fluid gel scaffolds, but the limitation of the study was that UV irradiation
was only administered for 20 minutes on each side of the gel, so it is possible that prolonged
UV exposure, such as 48 hours, may be more effective for terminal sterilisation of the gel.
Other potential terminal sterilisation methods that have been explored for alginate gels include
autoclaving and gamma-irradiation, which can both guarantee complete removal of bacterial
species, although they compromise the mechanical integrity of the gel structures and result in
degradation of polymer fibres. Ethylene oxide gas treatment has also been considered for ter-
minal sterilisation, but as a potentially toxic carcinogen, it is unsuitable for clinical use. One
treatment that has shown promise as a terminal sterilisation procedure is ethanol disinfection,
as it has demonstrated effective decontamination of 1.5 mm thick alginate hydrogels following
a 20-minute wash in 70% ethanol solution. Additionally, it allowed the mechanical and struc-
tural properties of the gel to be maintained and offers a cost-effective, but practical solution for
terminal sterilisation of alginate-based biomaterials [117]. Therefore, future work will require
examination of this procedure for use with alginate fluid gels, to determine its suitability and
efficacy.
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Figure 4.9: Calcein-AM/PI live/dead staining of BMAC cells in 2% w/v alginate fluid gel, cross-
linked with 0.1M CaCl2, after 7 days. Live and dead cells stain green and red, respectively, with
the majority of cells remaining viable following 7 days of culture within the fluid gel matrix.
4.3 Concluding statement
Alginate fluid gels of varying weight percentage were formulated using different production
profiles that displayed desirable functional properties in terms of their injectability. Although,
as could be anticipated, the 2% gel system demonstrated greater retention within model defects
and superior self-setting ability as a result of its increased shear-viscosity profile. Therefore,
this type of gel may be preferential in a clinical setting, where minimal operative time would
be favourable and would also minimise the risk of infection at the defect site. Following anal-
ysis of the fluid gel microstructure, it was revealed that there appears to be an alignment of
strands or fibres within the gel network that may have a direct influence on its mechanical prop-
erties. However, following preliminary experiments on the rheological properties of gels 48
hours post-formulation, there was a 10-20% reduction in the recorded storage modulus for 2%
alginate fluid gels produced using two different formulation procedures, thus highlighting the
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importance of conducting future degradation studies on these types of gels.
Finally, following the incorporation of an MC3T3 fibroblast cell population within alginate fluid
gels of varying weight percentage, the majority of cells expressed excellent viability over a 7-
day culture period and similar results were also seen with a population of human BMAC cells.
Whilst the results from these initial studies are promising, they emphasise the need to determine
the suitability and efficacy of terminal sterilisation procedures for alginate-based biomaterials
in order to sufficiently eliminate the presence of bacteria for clinical use, as these types of gel
cannot currently be manufactured under sterile conditions.
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CHAPTER 5
RESULTS CHAPTER 2: TAILORING RELEASE OF
KARTOGENIN AND THE BIOLOGICAL EFFECTS
ON A HETEROGENEOUS CELL POPULATION
WITHIN BMAC
As previously mentioned in Chapter 1, a therapeutic molecule, known as kartogenin (KGN), has
been shown to stimulate selective chondrogenic differentiation of stem cells, which could there-
fore be favourable in facilitating differentiation of progenitor cells when incorporated into the
fluid gel microenvironment. Consequently, studying the tailored release of this molecule from
alginate fluid gel scaffolds was investigated in this chapter, along with analysis of metabolic
activity by two different progenitor cell populations following external addition of KGN.
5.1 Materials and Methods
5.1.1 Materials
KGN and phosphate buffered saline (PBS) solution were purchased from Sigma-Aldrich and
DMSO was obtained from Fisher Scientific.
Chondrogenic media
DMEM/F12 ((1:1)(1X), Gibco 21331-020, Life Technologies, UK) with 1%vol, ITS-X (Gibco
51500-056, Life Technologies, UK), 2.4%vol HEPES Buffer (H0887, Sigma Aldrich, UK),
2.4%vol L-Glutamine (G7513, Sigma Aldrich, UK), 1%vol Penicillin/Streptomycin (P4333-
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100ml Sigma-Aldrich, UK), 100 nM Dexamethasone (SIgma-Aldrich D4902-100mg, UK),
27.5 µg/ml Ascorbic Acid (2-phospho-L-ascorbic acid (49752-10G, Sigma-Aldrich, UK), 1.25
µg/ml Bovine Serum Albumin (A8806-1G, Sigma-Aldrich, UK) and 10 ng/ml TGF-β1 (PHG9214,
Life Technologies).
Non-chondrogenic media
DMEM/F12 ((1:1)(1X), Gibco 21331-020, Life Technologies, UK) with 10% Fetal Bovine
Serum (FBS) (Sigma-Aldrich F7524, UK), 2.4%vol HEPES Buffer (H088, Sigma-Aldrich,
UK), 2.4%vol L-Glutamine (G7513, Sigma-Aldrich, UK), 1%vol Penicillin/Streptomycin (P4333-
100ml Sigma-Aldrich, UK).
5.1.2 Preparation of KGN fluid gel
A 1 mM KGN stock solution was prepared by dissolving 15.5 mg KGN in 50 ml DMSO. KGN
fluid gel was then produced by adding 30 µL of 1 mM KGN stock solution to the concentric
cylinder after the alginate solution during the fluid gel formulation process, described in 4.1.
5.1.3 In vitro release study
The release profile of KGN from fluid gel was determined by placing 1g of 2% alginate fluid
gel in 3 mL PBS solution, extracting 2.5ml of ageing media after 1hr, 12hrs, 24hrs and then
2, 3, 4, 5, 6, 7 days. The overall concentration of KGN in the fluid gel was 1µmolL−1. KGN
content in the liquid was estimated by absorbance at 277.8nm against a calibration curve using
ultraviolet-visible (UV-vis) spectrophotometry.
5.1.4 In vitro chondrogenic differentiation of rat bone marrow stromal
cells
Rat bone marrow stromal cells (rBMSCs) at passage 2 were seeded into 6-well plates at a
density of 9.62 x 104 cells per well, left to attach over 48 hours and exposed to varying con-
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centrations of KGN (0 nmolL−1-1 µmolL−1) through delivery in solution or via a 2% alginate
fluid gel matrix, crosslinked with 0.1 M calcium chloride. The cells were then supplied with
fresh high-glucose Dulbecco‘s modified Eagle‘s medium (DMEM) with 10% FBS, 1%vol Peni-
cillin/Streptomycin, and KGN doses every 3 days. Cells were cultured at 37°C in 5% CO2.
5.1.5 Histology
Following 14 days of treatment, the media was then removed so that the cells could be fixed with
ice cold 75% ethanol and subsequently stained for the detection of proteoglycans and collagen
within the culture plate wells with Safranin O solution and later Alcian blue (1% in 3% acetic
acid, pH 2.5, Sigma-Aldrich, UK).
5.1.6 In vitro chondrogenic differentiation of BM mononuclear cells
Following extraction from the ipsilateral iliac crest, heparinised bone marrow aspirate was fil-
tered and concentrated using the Harvest BMAC®, SmartPrep2® System. The BMAC samples
were then analysed in vitro, where they were cultured in 6-well plates, at 37°C, 5% CO2 in
CO2 incubator, with 500 µL of BMAC per well. Consistent volumes of BMAC were used as
opposed to a definitive concentration of mono-nucleated cells, as this was more reflective of
clinical practice [87]. The experiment was carried out in duplicate, as a result of infection de-
veloping in the third 6-well plate, and non-chondrogenic medium was used until cells became
confluent, when it was exchanged with either fresh non-chondrogenic medium, chondrogenic
medium, or non-chondrogenic medium supplemented with 100 nM, 200 nM or 400 nM of KGN
(dissolved in DMSO and further diluted using non-chondrogenic medium), thereby removing
any immunological and haematopoietic cells. This process was repeated every 2-3 days, with
spent media collected and frozen at -20°C until assays were performed. As an additional con-
trol, a population of hBMSCs were isolated and expanded from bone chips removed from the
femoral neck/head or tibial plateau, then subsequently plated at 1 x 105 cells per well at passage
2.
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5.1.7 GAG contents analysis
After a 21-day culture period, chondrogenesis was evaluated quantitatively using BlyscanTM
Sulfated Glycosaminoglycan Assay kit (Biocolor, Northern Ireland, UK). Sample absorbance
was measured within 96-well plates in triplicate, at a wavelength of 630 nm using a microplate
spectrophotometer. Cells were also examined for proteoglycan synthesis by staining with Al-
cian blue (1% in 3% acetic acid, pH 2.5, Sigma-Aldrich, UK). Briefly, cells were washed twice
with PBS before being fixed in 4% paraformaldehyde (PFA) for 15 minutes at room tempera-
ture. In sequence, cells were rinsed 3 times with PBS and stained with Alcian blue (1% in 3%
acetic acid, pH 2.5, Sigma-Aldrich, UK) for 30 minutes. Following this, cells were washed 3
times with 3% acetic acid for 2 minutes each and rinsed with dH20.
5.2 Results and discussion
5.2.1 Sustained KGN release from 2% alginate fluid gel over 7 days
The release profile of KGN incorporated within 2% w/v fluid gel system over a 7-day period was
determined. Preliminary testing involved analysing the absorbance spectrum of KGN heated to
60°C alongside that of unheated KGN in DMSO solution. The results were indistinguishable
and thus, the conclusion was drawn that incorporation of KGN within the formulation process
would most likely not have an effect on its chemical activity. However, more formal analysis
of the structure of the molecule will need to be undertaken in the future. Subsequently, a 2%
alginate fluid gel was produced with an overall KGN concentration of 1µM, of which the release
profile was determined by placing 1g of gel in 2.5ml of PBS, extracting the total volume of
ageing media after 1hr, 12hrs, 24hrs and then 2, 3, 4, 5, 6, 7 days (Fig. 5.2). The KGN content
in the liquid was then estimated by absorbance at 277.8nm against a calibration curve (Fig. 5.1)
using UV-vis spectrophotometry.
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Figure 5.1: Calibration curve of KGN concentration against absorbance at 277.8nm using UV-
vis spectrophotometry.
From Figure 5.2, there is no evidence of burst release of KGN from the gel, as initial release is
below detectable levels. There is, however, slow release of KGN after 24 hours, which steadily
increases for up to 96 hours, allowing faster release compared to other gel systems [14]. This
lack of immediate burst release is unusual, but promising with regard to clinical application.
Although, it is clear that there are some issues with this assay, as it indicates that after 72 hours,
concentrations greater than that which was initially incorporated into the gel (1 mM of KGN),
are being released. This is a result of possible DMSO and CaCl2 release from the gel; after only
a few hours, the release media appears to be composed of two immiscible liquids creating a blur-
riness of white light through the cuvette. This contributed approximately 0.170 in absorbance,
which is highly significant. However, following 1-2 hours post transfer to the cuvette, the effect
had dissipated leaving a clear liquid. These effects have been calibrated against, although fu-
ture experiments may account for this by allowing 1-2 hours before taking the final absorbance
measurement. There is also the possibility that precipitation of the CaCl2 with the PBS release
media is occurring, which was explored through accelerated ageing experiments that mimicked
46
the breakdown of the gel over days, by measuring the absorbance of 3mM of CaCl2 in 3mL
of PBS. This resulted in clear formation of precipitates in the release media, with simulated
burst release of all the CaCl2 from 1mL of fluid gel causing significant clouding. Clearly, this
would invalidate any samples measured using UV-vis spectrophotometry, as the Beer-Lambert
law only holds for analytes that are homogeneously distributed in the media and the precipitates
cannot be modelled or calibrated out. Therefore, in future studies, it will be necessary to make
notes on sample turbidity and the presence of precipitates in test runs, otherwise it may be more
suitable to use an alternative release medium to PBS, if precipitates are observed at longer time
points.
An additional observation that was made was the sensitivity of the assay to small changes in
KGN concentration, which was illustrated by only a 0.1 change in absorbance covering the
250nM to 1000nM concentration range. Therefore, great care must be taken in handling the
sources of error in preparing the KGN solution. Furthermore, the calibration curve helped clar-
ify an estimate of the lower limit of detection (LLOD) for KGN in the region of 10-100nM,
as there is no change in absorbance between 1nM and 10nM (both have absorbance values of
0.08). Thus, this leads to the conclusion that the LLOD for the assay will be at least 10nM,
though its precise value is yet to be determined and explains why the calibration curve plateaus
at low concentrations of KGN release in the samples. This can also be seen in the case of the
first time point in the KGN release figure, which is out of the detection range.
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Figure 5.2: Sustained KGN release from 2% alginate fluid gel over 7 days in PBS media, with
continuous slow release of KGN following 24 hours.
5.2.2 Safranin O and Alcian blue staining of rBMSC’s following 14 days
culture and treatment with KGN
One of the key objectives is to deliver and maintain the viability of a progenitor cell population,
which has been successfully achieved through incorporation of a rat bone marrow stromal cell
(rBMSC) population within the fluid gel matrix, with metabolic activity being assessed through
analysis of cartilage matrix production following external addition of KGN. As illustrated in
Figure 5.3, over a 14-day period and following staining with Safranin O and Alcian Blue solu-
tion, production of both proteoglycans and collagen was observed, with evidence of costaining
in some regions that suggests structuring of an organised matrix by rat bone marrow stromal
cells (rBMSCs), particularly at 10nM.
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Figure 5.3: Safranin O and Alcian Blue staining of rBMSC’s following 14 days of treatment
with KGN, illustrating production of both proteoglycans and collagen, with evidence of costain-
ing suggesting structuring of an organised matrix, particularly at 10nM.
5.2.3 DMMB assay and Alcian blue staining of BMAC and hBM-MSC
cells following 21 days culture and treatment with KGN
Proceeding from the investigation of rBMSCs, following 14 days of treatment with KGN, a
similar study was undertaken to examine the effect of KGN on BMAC in comparison to a pop-
ulation of human BM-MSCs (hBM-MSCs), as a positive control. Effective known doses of
KGN in non-chondrogenic media were delivered over a 21-day chondrogenic culture period,
within 6-well plates and chondrogenesis was determined using both Alcian blue staining and
a DMMB assay to identify the production of proteoglycans. Promisingly, brightfield images
indicated a large proportion of the BMAC and hBM-MSC cells were alive following the 21-day
chondrogenic culture period (Fig. 5.4 and Fig. 5.5).
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The results shown in Figures 5.6 illustrate the effect of 100nM KGN treatment on hBM-MSCs
and BMAC, over a 21-day period, with higher GAG concentrations being detected at days 0,
7 and 21, following the collection of spent media from cultured BMAC cells. Similar results
were seen following 200nM KGN treatment (5.7), although there were only minor changes in
GAG concentration for each cell type over the 21-day period. In Figure 5.8, there were greater
changes in GAG concentration, following 400nM KGN treatment, with the largest increase
being seen on day 14 in hBM-MSC cells. Although, this may be a result of the larger errors
in measurement at this concentration. This is also evident in Figure 5.9, where 400nM KGN
treatment appears to have the greatest influence on GAG production in hBM-MSCs after 14
days culture. However, the results for treatment with 100nM KGN were more consistent, with
increases in GAG concentration being measured gradually up to day 21, when they decreased,
possibly due to cell apoptosis from a minor infection developing in wells containing hBM-
MSCs. Additionally, BMAC cells responded favourably to treatment with 100nM KGN, as
illustrated in Figure 5.10, followed closely by treatment with chondrogenic media, though it
was clear there were similar decreases in GAG concentration by day 21. Visual staining of
proteoglycans by Alcian blue can also be seen in Figure 5.11, however there was generally
minimal staining across both sets of plates.
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Figure 5.4: Brightfield images of unstained cells indicate that the majority of BMAC cells were
alive after approximately 21 days of culture. Abbreviations used: non-chondrogenic medium
(CH-), chondrogenic medium (CH+), non-chondrogenic medium supplemented with 100 nM
(100nM), 200 nM (200nM) or 400 nM (400nM) of KGN (dissolved in DMSO and further
diluted using non-chondrogenic medium).
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Figure 5.5: Brightfield images of unstained cells indicate that the majority of hBM-MSC cells
were alive after approximately 21 days of culture. Abbreviations used: non-chondrogenic
medium (CH-), chondrogenic medium (CH+), non-chondrogenic medium supplemented with
100 nM (100nM), 200 nM (200nM) or 400 nM (400nM) of KGN (dissolved in DMSO and


























Figure 5.6: DMMB assay results following the treatment of hBM-MSCs and BMAC with




























Figure 5.7: DMMB assay results following the treatment of hBM-MSCs and BMAC with


























Figure 5.8: DDMMB assay results following the treatment of hBM-MSCs and BMAC with
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Figure 5.9: DMMB assay results following the treatment of hBM-MSCs with varying concen-
trations of KGN over 21 days. Abbreviations used: non-chondrogenic medium (CH-), chon-
drogenic medium (CH+), non-chondrogenic medium supplemented with 100 nM (100nM), 200
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Figure 5.10: DMMB assay results following the treatment of BMAC with varying concentra-
tions of KGN over 21 days. Abbreviations used: non-chondrogenic medium (CH-), chondro-
genic medium (CH+), non-chondrogenic medium supplemented with 100 nM (100nM), 200
nM (200nM) or 400 nM (400nM) of KGN (dissolved in DMSO and further diluted using non-
chondrogenic medium).
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(a) BMAC plates (b) hBM-MSC plates
Figure 5.11: Alcian blue staining of proteoglycans produced by BMAC and hBM-MSC cells.
Abbreviations used: non-chondrogenic medium (CH-), chondrogenic medium (CH+), non-
chondrogenic medium supplemented with 100 nM (100nM), 200 nM (200nM) or 400 nM
(400nM) of KGN (dissolved in DMSO and further diluted using non-chondrogenic medium).
Overall, the results from the DMMB assay of hBM-MSC and BMAC cells demonstrated a
marginal increase in GAG concentration produced by cells within the BMAC population com-
pared to the hBMSC population, although statistically there was no significant difference be-
tween the different sample populations for BMAC and hBM-MSCs. Despite noticing some
infection in the chondrogenic wells of the plates containing hBM-MSCs, it seems clear from
the light microscope images shown in Figures 5.4 and 5.5 that the majority of cells across both
sets of plates remained viable after 21 days of culture. Still, there appears to be a difference
between in confluency, with the hBM-MSCs appearing less confluent than the population of
BMAC cells. This could have been a result of the infection in the wells containing hBM-MSCs,
or it could be that chondrogenesis was induced prior to hBM-MSCs becoming fully conflu-
57
ent. Altogether, these results were attributed to the 2D culture environment and conditions used
with the aim of enabling minimal manipulation of BMAC samples prior to culturing, whereas
chondrogenic differentiation of MSCs is primarily carried out using micromass pellet culture
to create and provide a three-dimensional hypoxic environment that facilitates cell-cell inter-
actions, which recapitulates pre-chondrogenic condensations experienced in the early stages of
embryonic development. This could elucidate the decreasing trend in GAG concentration seen
for both hBM-MSC and BMAC cells, as cells differentiate along a more fibroblastic pheno-
type. Reduction in oxygen tension is also a key element in stimulating the production of VEGF
through hypoxic inducible factor (HIF-1), highlighting its significance in cartilage growth, as
VEGF reportedly enhances cell viability via expression of anti-apoptotic molecules [118, 81].
5.3 Concluding statement
A therapeutic molecule, known as kartogenin (KGN), that has been shown to stimulate selec-
tive chondrogenic differentiation of stem cells, was successfully incorporated into an alginate
fluid gel scaffold and displayed a steady release profile over a 7-day period. The system ex-
hibited a lack of immediate burst release, which, though unusual, is promising with regard to
clinical application. However, there were some clear issues with the assay, indicating higher
concentrations of KGN being released from the gel than were actually incorporated. This was
possibly caused by the formation of precipitates from the CaCl2 present within the gel and
thus, invalidated any samples measured using UV-vis spectrophotometry, due to invalidation of
the Beer-Lambert law. Future work may therefore consider the use of a more suitable release
medium to PBS, as well as the use of high performance liquid chromatography (HPLC), which
is more sensitive for assaying small changes in concentration.
Subsequent to the release studies with KGN, the metabolic activity of two different progenitor
cell populations within the fluid gel matrix were assessed following external addition of KGN.
Firstly, analysis of cartilage matrix production by a rat bone marrow stromal cell (rBMSC)
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population was assessed over a 14-day culture period, displaying evidence of proteoglycan and
collagen production, particularly at 10nM. Further work then compared the effect of KGN on
both human BMAC and BM-MSC (hBM-MSC) cell populations over a 21-day culture period.
Promisingly, a substantial proportion of cells appeared to be alive following the 21-day chondro-
genic culture period, although statistically there was no significant difference in proteoglycan
production between the different sample populations for BMAC and hBM-MSCs. Altogether,
these results were attributed to the 2D culture environment and conditions used with the aim
of enabling minimal manipulation of BMAC samples prior to culturing, whereas chondrogenic
differentiation of MSCs is primarily carried out using micromass pellet culture to create and
provide a three-dimensional hypoxic environment that facilitates cell-cell interactions, which
recapitulates pre-chondrogenic condensations experienced in the early stages of embryonic de-
velopment. In summary, this illustrates the importance of constructing a simulative culture
system to enable a three-dimensional extracellular matrix to develop, as it is clear that the other
two prerequisites of chondrogenesis; addition of serum-free medium and a TGF-isoform, are
conditional upon this requirement [102].
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
6.1 Conclusions
This work has involved the development of a self-setting gel system for kartogenin delivery in
the form of an injectable alginate fluid-gel microenvironment and scaffold that is capable of
supporting cell viability and be retained within model defects. This biomaterial can be formu-
lated to steadily release effective known doses of KGN over a 7-day period, although there were
notably some issues with the assay using UV-vis spectrophotometry, due to invalidation of the
Beer-Lambert Law. Therefore, future work could consider the use of a more suitable release
medium to PBS, as well as the use of high performance liquid chromatography (HPLC), which
is more sensitive for assaying small changes in concentration. Finally, the potential of the fluid
gel microenvironment in promoting the chondrogenic differentiation of BMSCs and a hetero-
geneous BMAC cell population demonstrated initial promise, though further work is needed to
corroborate these preliminary findings.
6.2 Recommendations for future work
Future work will include further characterisation of the fluid gel microstructure, through both
phase contrast and confocal microscopy by fluorescently labelling the alginate biopolymer. Ad-
ditionally, it is important that the effect of KGN on BMAC in comparison to a population
of human BM-MSCs (hBM-MSCs) is reassessed using micromass pellet culture, in order to
formally determine whether the existing results can be indeed be attributed to the 2D culture
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environment and conditions that were used. As previously mentioned, it will also be essential
to conduct long term degradation studies of the fluid gel systems, which was highlighted during
the mechanical testing process, as this will clearly impact the retention and metabolic activity
of delivered cells at the defect site during the healing process.
Further down the line, it will be necessary to examine methods of terminal sterilisation for the
cell delivery vehicle, specifically prolonged UV irradiation, for example 24- or 48-hour expo-
sure, as well as ethanol disinfection. Finally, it would be beneficial to explore refinement of
the gel formulation, in order to achieve a more homogenous structure, which may be achiev-
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